Valeant Pharmaceuticals Acquires U.S. Rights to Targretin from Eisai

Thu, 02/21/2013 - 8:10am

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Valeant Pharmaceuticals International, Inc.  announced today that Valeant has acquired U.S. rights for Targretin (bexarotene) capsules and Targretin (bexarotene) gel 1% from Eisai for $65 million upfront, plus potential contingent payments based on certain milestones
As part of the transaction, which takes effect immediately, Eisai has transferred the New Drug Application (NDA) for Targretin to Valeant, with Valeant assuming responsibilities for all regulatory obligations associated with the product in the United States. Eisai will retain its rights to Targretin outside of the United States and continue to meet the needs of its distribution partners outside of the United States.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.